Blueprint Medicines Corporation (BPMC): Price and Financial Metrics
BPMC Price/Volume Stats
Current price | $48.86 | 52-week high | $68.63 |
Prev. close | $50.22 | 52-week low | $37.82 |
Day low | $47.84 | Volume | 406,900 |
Day high | $50.00 | Avg. volume | 599,135 |
50-day MA | $51.77 | Dividend yield | N/A |
200-day MA | $50.54 | Market Cap | 2.96B |
BPMC Stock Price Chart Interactive Chart >
BPMC POWR Grades
- Sentiment is the dimension where BPMC ranks best; there it ranks ahead of 60.3% of US stocks.
- BPMC's strongest trending metric is Growth; it's been moving up over the last 177 days.
- BPMC's current lowest rank is in the Stability metric (where it is better than 9.59% of US stocks).
BPMC Stock Summary
- Of note is the ratio of BLUEPRINT MEDICINES CORP's sales and general administrative expense to its total operating expenses; just 16.57% of US stocks have a lower such ratio.
- With a price/sales ratio of 13.32, BLUEPRINT MEDICINES CORP has a higher such ratio than 92.55% of stocks in our set.
- With a year-over-year growth in debt of 121.52%, BLUEPRINT MEDICINES CORP's debt growth rate surpasses 90.89% of about US stocks.
- Stocks that are quantitatively similar to BPMC, based on their financial statements, market capitalization, and price volatility, are SLDP, ADVM, DCPH, FULC, and MCRB.
- Visit BPMC's SEC page to see the company's official filings. To visit the company's web site, go to www.blueprintmedicines.com.
BPMC Valuation Summary
- In comparison to the median Healthcare stock, BPMC's price/sales ratio is 600% higher, now standing at 13.3.
- Over the past 102 months, BPMC's EV/EBIT ratio has gone up 4.8.
Below are key valuation metrics over time for BPMC.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BPMC | 2023-09-22 | 13.3 | 9.7 | -5.4 | -6.0 |
BPMC | 2023-09-21 | 13.3 | 9.6 | -5.4 | -6.0 |
BPMC | 2023-09-20 | 13.6 | 9.9 | -5.5 | -6.2 |
BPMC | 2023-09-19 | 13.8 | 10.0 | -5.6 | -6.2 |
BPMC | 2023-09-18 | 14.0 | 10.2 | -5.7 | -6.3 |
BPMC | 2023-09-15 | 13.6 | 9.9 | -5.5 | -6.2 |
BPMC Growth Metrics
- The 2 year price growth rate now stands at 6.53%.
- The 4 year cash and equivalents growth rate now stands at 560.04%.
- Its 2 year net income to common stockholders growth rate is now at -75.19%.

The table below shows BPMC's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 272.276 | -394.986 | -717.557 |
2022-06-30 | 230.487 | -360.692 | -701.635 |
2022-03-31 | 221.235 | -305.601 | -650.37 |
2021-12-31 | 180.08 | -298.653 | -644.085 |
2021-09-30 | 107.165 | -309.338 | -411.067 |
2021-06-30 | 828.095 | 408.584 | 340.152 |
BPMC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BPMC has a Quality Grade of C, ranking ahead of 33.2% of graded US stocks.
- BPMC's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
- OTLC, SGEN, and OCGN are the stocks whose asset turnover ratios are most correlated with BPMC.
The table below shows BPMC's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.067 | 0.871 | -0.440 |
2021-06-30 | 0.512 | 0.992 | 0.352 |
2021-03-31 | 0.566 | 0.999 | 0.382 |
2020-12-31 | 0.634 | 0.999 | 0.411 |
2020-09-30 | 0.812 | 1.000 | 0.485 |
2020-06-30 | 0.095 | 0.998 | -0.729 |
BPMC Price Target
For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $119.69 | Average Broker Recommendation | 1.47 (Moderate Buy) |
Blueprint Medicines Corporation (BPMC) Company Bio
Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Latest BPMC News From Around the Web
Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
Director Jeffrey Albers Sells 25,000 Shares of Blueprint Medicines CorpOn September 28, 2023, Jeffrey Albers, a director at Blueprint Medicines Corp (NASDAQ:BPMC), sold 25,000 shares of the company's stock. |
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 8,446 shares of its common stock and an aggregate of 4,221 restricted stock units (RSUs) to six new employees under Blueprint Medicines' 2020 Inducement Plan. |
Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
BPMC Price Returns
1-mo | -3.52% |
3-mo | N/A |
6-mo | 15.26% |
1-year | -25.85% |
3-year | -46.94% |
5-year | -34.20% |
YTD | 11.53% |
2022 | -59.10% |
2021 | -4.49% |
2020 | 40.00% |
2019 | 48.60% |
2018 | -28.51% |
Continue Researching BPMC
Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...